HUMA - Humacyte gains as Piper Sandler upgrades after Q2 results
2023-08-14 12:38:34 ET
More on Humacyte
- Humacyte gains 10% after $160M funding from Oberland
- Humacyte stock dips after Q4 sees net loss, no grant revenue
- Humacyte plunges as Piper downgrades citing further weakness ahead
- Humacyte to provide Ukraine hospitals HAVs to treat vascular trauma injuries
- Seeking Alpha’s Quant Rating on Humacyte
For further details see:
Humacyte gains as Piper Sandler upgrades after Q2 results